Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation

Fig. 2

TRPM7 silencing shifts glycolysis to OXPHOS in ovarian cancer cells. A The effect of TRPM7 silencing on the glucose uptake levels, (B) extracellular lactate levels, (C) ECARs, (D) OCRs, (E) NAD+/NADH ratios, (F) ATP levels, (G) intracellular ROS levels in SKOV3 and HO8910 cells. H IHC analysis of TRPM7 expression in SKOV3 xenograft tumors. Scale bar = 50 μm. I Representative photographs of 18F-FDG PET/CT scans of SKOV3 xenograft tumors in mice following treatment with, or without, carvacrol, a potent inhibitor of TRPM7. SKOV3 and carvacrol were injected to right forelimbs. The SUV max was lower in the carvacrol group than in the control group (n = 7 per group)

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us